1. Interstitial lung disease (ILD): ILD occurred in patients taking Gefitinib. Should withheld Gefitinib for worsening of respiratory symptoms. Need to discontinue Gefitinib if ILD is confirmed.
2. Hepatotoxicity: Should withheld Gefitinib for Grade 2 or higher for ALT and/or AST elevations. Should discontinue for severe hepatic impairment.
3. Gastrointestinal perforation: Discontinue Gefitinib for gastrointestinal perforation.
4. Diarrhea: Withhold Gefitinib for Grade 3 or higher diarrhea.
5. Ocular Disorders including Keratitis: For signs and symptoms of severe or worsening ocular disorders including keratitis Gefitinib should be withheld.
6. Embryo-fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.
.jpg){kind=link}
